Groundbreaking Stanford Study Reverses Type 1 Diabetes in Mice with Novel Immune System Reset
A revolutionary approach involving blood stem cell and islet cell transplantation has entirely reversed or prevented Type 1 diabetes in mice, offering a beacon of hope for a potential cure in humans. Researchers at stanford Medicine achieved this breakthrough by creating a “hybrid” immune system in the animals, effectively halting the autoimmune attack on insulin-producing cells and eliminating the need for lifelong immunosuppression or insulin injections.
The study, published online November 18 in the Journal of Clinical Investigation, builds upon years of research into immune tolerance and the potential of stem cell therapies. Type 1 diabetes occurs when the body’s immune system mistakenly identifies and destroys the insulin-producing islet cells in the pancreas, leaving patients dependent on external insulin to survive.
A Two-Pronged Approach to Immune Reset
The Stanford team, led by Seung K. Kim, MD, PhD, tackled the complex challenge of both replacing lost islet cells and resetting the immune system to prevent further destruction. Unlike previous attempts focused solely on immune suppression, this strategy combined a low dose of radiation to deplete the existing immune system with a transplant of blood stem cells from a donor, followed by a transplant of pancreatic islet cells.
The results were striking. in 19 out of 19 cases, mice did not develop Type 1 diabetes after receiving the combined transplant.Even more encouraging, nine out of nine animals with long-standing type 1 diabetes experienced a complete reversal of the disease. Following the transplants, the mice required no further immune suppressive drugs or insulin for the duration of the six-month study.
A key to the success was a simple adjustment to the pre-transplant protocol. Researchers added a medication commonly used to treat autoimmune diseases, enhancing the effectiveness of the initial immune readiness. This tweak allowed for the development of the hybrid immune system without triggering harmful immune responses.
Building on Prior Successes and Kidney Transplant Research
This research extends a 2022 study by Kim and his collaborators, which demonstrated blood sugar control restoration in mice using a similar approach. The current work also draws upon decades of research led by the late Samuel Strober, MD, PhD, and Judith shizuru, MD, phd, at Stanford. their earlier work showed that bone marrow transplants could create hybrid immune systems in humans, enabling long-term acceptance of kidney transplants without the need for ongoing immunosuppression.
“Based on many years of basic research by us and others, we know that blood stem cell transplants could also be beneficial for a wide range of autoimmune diseases,” said Shizuru. The team has pioneered a safer, less intense method of preparing patients for blood stem cell transplantation, minimizing the risks associated with conventional high-dose chemotherapy and radiation.
Looking Ahead: Clinical Trials and Broader Applications
The researchers are optimistic about translating these findings to human clinical trials. As the antibodies, drugs, and low-dose radiation used in the mouse studies are already part of standard clinical practice for blood stem cell transplantation, the path to human trials appears feasible.
However, challenges remain. Obtaining sufficient pancreatic islets from deceased donors is a important hurdle, as is ensuring that the number of islet cells is adequate to reverse established Type 1 diabetes. Scientists are exploring methods to generate large quantities of islet cells in the laboratory from pluripotent human stem cells and to improve the survival and function of transplanted islets.
Beyond Type 1 diabetes, the team believes this approach could have far-reaching implications for other autoimmune diseases, such as rheumatoid arthritis and lupus, as well as for non-cancerous blood disorders like sickle cell anemia and for improving outcomes in mismatched solid organ transplants. “The ability to reset the immune system safely to permit durable organ replacement could rapidly lead to great medical advances,” Kim concluded.
The study was funded by the National institutes of Health (grants T32 GM736543, R01 DK107507, R01 DK108817, U01 DK123743, P30 DK116074 and LAUNCH 1TL1DK139565-0), the Breakthrough T1D Northern California Center of Excellence, Stanford Bio-X, the Reid Family, the H.L. Snyder Foundation and Elser Trust, the VPUE Research Fellowship at Stanford, and the Stanford Diabetes Research Center.
